Secondary Logo

Journal Logo

Review Article

Endophthalmitis Prophylaxis for Cataract Surgery

Haripriya, Aravind MD*; Baam, Zervin R. MS*; Chang, David F. MD

Author Information
Asia-Pacific Journal of Ophthalmology: July 2017 - Volume 6 - Issue 4 - p 324-329
doi: 10.22608/APO.2017200
  • Free

Abstract

Endophthalmitis, although very rare, is one of the most serious postoperative complications of ocular surgery. Infectious postoperative endophthalmitis is caused by entry of microorganisms into the eye during or after the surgical procedure. Although it can occur with any intraocular surgery, most cases are associated with cataract surgery, as it is the most common eye operation performed.1

The reported rate of endophthalmitis after cataract surgery ranges from 0.03% to 0.70%.2,3 There has been wide variation in the postoperative endophthalmitis rate over time, with the rate reported to be 0.087% in 1990 and 0.265% in 2000.2 It has been hypothesized that the increased rate observed during the 1990s was related to the use of sutureless, clear corneal incisions (CCIs) during phacoemulsification.2,4,5 There are also some studies that seem to discredit this hypothesis and instead suggest that CCIs may be associated with less endophthalmitis.6,7 Advanced age (>85 years old), rural residence, male sex, and immunosuppressive states such as diabetes mellitus may be patient-associated risk factors.8-10 The European Society of Cataract and Refractive Surgeons (ESCRS) multicenter prospective study11 identified 3 factors that significantly increased the risk of postoperative infectious endophthalmitis: a CCI, silicone intraocular lenses (IOLs), and the occurrence of surgical complications.

According to the Endophthalmitis Vitrectomy Study (EVS),12 most affected individuals lose visual acuity permanently, and visual outcomes are often are poor. One third of individuals do not gain vision better than counting fingers, and 50% do not recover vision better than 20/40.13 A more recent study reported that 34% of affected patients achieved a final visual acuity of 20/200 or worse.14 With the significant increase in cataract surgery due to population aging worldwide, effective endophthalmitis prophylaxis is a rising global imperative.

MATERIALS AND METHODS

We reviewed the recent literature using the PubMed database to identify original articles using the key words “endophthalmitis prophylaxis,” “povidone iodine cataract surgery,” and “intracameral antibiotic prophylaxis.” Additional advanced search criteria included the time period from January 1, 2008, to December 30, 2016, humans, and English language. Special consideration was focused on all articles published on this topic in the past 18 months.

RESULTS

In recent years, trends in endophthalmitis prophylaxis have evolved considerably. Both surgical and nonsurgical preventive strategies have been advocated.15 We highlight a number of options and global practices below.

Povidone-Iodine Prophylaxis

The single most effective method of preoperative antisepsis is the application of povidone-iodine (PVI) solution (5-10%) to the cornea, the conjunctival sac, and the periocular skin surface for a minimum of 3 minutes before the commencement of surgery.16 This results in a significant decrease in the ocular surface microbial flora and has been convincingly shown to reduce endophthalmitis rates.11,17-22 The systematic implementation of PVI prophylaxis was the single most important factor for endophthalmitis reduction at an institution during a 20-year period of analysis.23 Shimada et al24 recently reported that the rate of anterior chamber bacterial contamination was significantly lessened when the operative field was irrigated every 20 seconds with balanced salt solution (BSS) containing 0.025% or 0.0025% PVI (0% rate) compared with irrigation with BSS alone (5% rate).24 There was no difference in endothelial cell density or postoperative inflammation among the 3 groups. When PVI is contraindicated (true allergy is rare and hyperthyroidism is a relative contraindication),25 aqueous chlorhexidine 0.05% may be used.11 Preoperative antisepsis of the periocular area with topical PVI is widely adopted and is considered the standard of care for endophthalmitis prevention.26,27

Perioperative Topical Antibiotics

Antibiotic prophylaxis is another common preventive measure. However, there is wide variation in the antibiotic agents used (eg, fluoroquinolones, aminoglycosides, cephalosporins, chloramphenicol), the administration routes (topical, intraocular, subconjunctival, oral), and the timing (preoperative, intraoperative, perioperative, postoperative).26,28,32 The most common causative bacteria are Gram-positive species, such as coagulase-negative Staphylococcus (CoNS), Streptococcus viridans, or Staphylococcus aureus.33,34 Gram-negative organisms, such as Pseudomonas or Haemophilus, are less common; fungi and Nocardia are rare.3,15,35,36

There is wide variability in the use of topical antibiotic prophylaxis. In contrast to PVI prep, the evidence supporting topical antibiotic prophylaxis is not as compelling, leading some surgeons to forgo it entirely.37 The theoretical goal of topical antibiotic prophylaxis is to reduce the conjunctival bacterial load, thereby lowering the risk of intraocular contamination either intraoperatively or postoperatively. Strong evidence to support its efficacy is lacking, and there is the theoretical risk that prolonged and repeated administration may induce bacterial antibiotic resistance.11 The vast majority of respondents in the 2014 American Society of Cataract and Refractive Surgery (ASCRS) survey (90%) used topical perioperative antibiotics and virtually all surgeons used them postoperatively (97%). The American Academy of Ophthalmology Cataract Preferred Practice Pattern cites that starting topical antibiotics on the day of surgery seems to be preferable to waiting until the next day to initiate them.38 Topical antibiotics are frequently used for up to 1-2 weeks postoperatively until the incision fully heals and should not be tapered, as this would encourage emergence of resistant organisms.

Intracameral Antibiotics

Corneal incisions may permit influx of fluid during surgery and even after hydration of the main incision and side port. Despite using preoperative antibiotics and povidone-iodine and following careful sterilization and aseptic protocols, the rate of intraocular bacterial contamination has been shown to be as high as 31%.39 Similar rates of anterior chamber contamination have been reported with both phacoemulsification and manual small-incision cataract surgery (M-SICS).40 Injecting antibiotics intracamerally (IC) at the end of surgery is intended to kill bacterial microbes that have been introduced during the procedure. This practice is becoming more popular worldwide. The 2014 ASCRS endophthalmitis prophylaxis survey found that 50% of the 1147 global respondents injected an IC antibiotic at the conclusion of surgery.41 This is significantly more than in the comparable 2007 ASCRS endophthalmitis prophylaxis survey, where 30% of respondents were using intraocular antibiotic prophylaxis.42 Antibiotics for intracameral use should have broad antimicrobial coverage and have the least potential for toxicity. The most commonly used antibiotics for intraocular prophylaxis are cephalosporins (cefuroxime and cefazolin), vancomycin, and moxifloxacin.

Cefuroxime

Cefuroxime, a second-generation cephalosporin, was initially studied for intracameral prophylaxis by Montan et al43,44 in the early 1990s. In 2006, the prospective, multicenter ESCRS endophthalmitis prophylaxis study reported a significant reduction in endophthalmitis rates with IC cefuroxime injection.9,45 This landmark randomized controlled trial enrolled 16,603 total patients and provides the strongest support for the efficacy of intracameral antibiotic prophylaxis. The rates of culture-proven endophthalmitis in the 2 groups receiving intracameral cefuroxime prophylaxis were 0.050% and 0.025% compared with 0.226% and 0.176% in the 2 groups without intracameral antibiotic. Overall, direct intracameral cefuroxime injections resulted in a 5.86-fold decrease in the rate of culture-positive endophthalmitis. A large number of international retrospective studies5,44,46-53 have also found a significant decrease in the postoperative endophthalmitis rate after initiation of intracameral cefuroxime prophylaxis. One such long-term study from France54 reported on 6,371,242 eyes over the 10-year period from 2005 to 2014. During this period, a significant decrease in endophthalmitis coincided with the commercial availability of cefuroxime for intracameral injection. Two large studies from Spain reported an approximately 10-fold reduction in endophthalmitis rates with IC cefazolin injections.55,56

The approval in multiple European countries of a commercial cefuroxime preparation for intracameral injection (Aprokam, Thea) has led to a significant increase in intracameral antibiotic prophylaxis in these countries.47 The 2013 ESCRS endophthalmitis prophylaxis guidelines support using a commercially approved cefuroxime formulation based on the published evidence.11 A 2014 ESCRS survey showed that 74% of the respondents regularly employed intracameral antibiotic prophylaxis. However, Aprokam is largely unavailable outside of the European region. This may explain why the 2014 ASCRS survey found that, in addition to cefuroxime, vancomycin and moxifloxacin are also commonly used by those respondents injecting antibiotics intracamerally.

Recently, there have been several reports of endophthalmitis caused by cefuroxime-resistant organisms. Data from the Swedish National Cataract Surgery Database suggests that the overall postoperative endophthalmitis rates with intracameral cefuroxime and moxifloxacin were similar.57 However, postoperative endophthalmitis after cefuroxime prophylaxis was associated with worse visual outcomes, largely due to a higher proportion of cases infected with resistant Enterobacter species. This raised a concern over increasing rates of cefuroxime-resistant Gram-negative isolates in Sweden. At least 2 cases of anaphylaxis associated with intracameral cefuroxime injection have been reported in the literature.58,59

Vancomycin

Vancomycin is a broad-spectrum antibiotic that covers nearly all staphylococcal and streptococcal species, the most frequent causes of postoperative endophthalmitis after cataract surgery. It has been a common choice for intraocular endophthalmitis prophylaxis, but there is no preparation that is commercially approved for intracameral use. Most commonly, 1 mg/0.1 mL of the drug is injected intracamerally at the end of surgery. In the 2014 ASCRS survey this was the most commonly used antibiotic among those respondents employing intracameral prophylaxis: 37% overall and 52% of American respondents. However in 2015, Witkin et al60 reported on 6 patients that had an extremely rare but devastating complication associated with intracameral vancomycin: hemorrhagic occlusive retinal vasculitis (HORV). Findings of a joint ASCRS-American Society of Retina Specialists (ASRS) task force on HORV were subsequently published and included 36 eyes from 23 patients (13 bilateral cases).61 Every single case occurred after uncomplicated cataract surgery in which intraocular vancomycin was administered. Hemorrhagic occlusive retinal vasculitis seems to be a type III hypersensitivity reaction because the onset is delayed (mean onset after 1 week) and exposure of the second eye results in an earlier and more severe vasculitis. Outcomes are frequently poor because of rapid onset of neovascular glaucoma. Although likely very rare, the true incidence of this devastating complication is unknown, and many surgeons have abandoned vancomycin for routine endophthalmitis prophylaxis.

Moxifloxacin

Moxifloxacin is a fourth generation fluoroquinolone that was approved for systemic use in the United States in 1999 and for topical ophthalmic use in 2003. It has excellent ocular penetration after topical administration and reduced susceptibility to the emergence of bacterial resistance, which is dose-dependent as opposed to absolute.62-64 There is a trend of increasing resistance of CoNS to third and fourth generation fluoroquinolones.65 However, intracameral moxifloxacin achieves bactericidal levels at least 10 times the minimum inhibitory concentration of the most resistant bacteria for a limited time period but, because of its potent dose-dependent activity even at low injection concentrations, it remains bactericidal for a much longer duration than cefuroxime.65 In many countries, such as the United States, moxifloxacin can be compounded for intracameral prophylaxis by outsourcing to compounding pharmacies. Intracameral injection of Vigamox brand topical moxifloxacin, which is unpreserved, is a more popular option.30 Several studies have reported on the method and the safety of using the topical brand Vigamox for intracameral prophylaxis.66,67 Generic topical moxifloxacin contains preservatives and other adjuvants that are not safe for intraocular use.

In India and several other countries outside Europe and the United States, specific intracameral preparations of moxifloxacin have been available since 2013, including Auromox 0.5% (Aurolab, Madurai, India) single-use 1 mL vials and 4-Quin PFS 0.5% (Entod Pharmaceutical, India) single-use prefilled syringes. Injection of 0.1 mL containing 500 μg of these ready-to-use commercial preparations achieves anterior chamber concentrations exceeding 1 mg/mL. Our early experience using intracameral moxifloxacin (Auromox, Aurolab, India) for endophthalmitis prophylaxis on charity patients of the Aravind Eye Hospital in Madurai showed a significant 4-fold reduction in the endophthalmitis rate in eyes that underwent M-SICS.68 Based on this positive experience, routine intracameral moxifloxacin prophylaxis became standard at all 10 surgical facilities of the Aravind Eye Care System. When the endophthalmitis rate was analyzed in more than 600,000 consecutive cataract surgeries performed over a 2.5-year period, we saw a significant overall endophthalmitis reduction from 0.07% to 0.02%. This was separately true for both phacoemulsification (7-fold) and M-SICS (3.5-fold) and at each of the large regional centers individually.33Table 1 summarizes recent large retrospective studies that support the efficacy of intracameral antibiotics for endophthalmitis prophylaxis.

TABLE 1
TABLE 1:
Most Recent Retrospective Studies Comparing Endophthalmitis Rates With and Without Intracameral Antibiotic (Published Since 2012)

Although the debate regarding the safety and efficacy of using intracameral antibiotic prophylaxis continues, a recent Cochrane review69 analyzed studies that had been published through December 2016 and concluded that the 2007 ESCRS study demonstrated the efficacy of using intracameral antibiotics for reducing endophthalmitis. However, the antibiotic of choice may differ based on the clinical setting. Although there may be concerns regarding toxicity and contamination with cefuroxime, increasing resistance to endophthalmitis-causing organisms may be the concern with moxifloxacin. This review also cited the fact that clinical trials with rare outcomes require very large sample sizes and are very costly to conduct. This explains why most published evidence regarding postoperative endophthalmitis comes from retrospective trials and that practitioners must consider different types of studies to make informed decisions regarding endophthalmitis prophylaxis.

DISCUSSION

Javitt's75 oft-cited editorial elegantly summarizes the multiple reasons that a prospective randomized placebo controlled trial is so difficult, expensive, impractical, and potentially unethical to now perform.

Although there is strong evidence supporting the efficacy of intracameral antibiotic prophylaxis, the most important deterrent seems to be the lack of a commercially approved preparation in most countries, and this explains the wide global variation in this practice.76 Mixing antibiotics in the operating room raises the theoretical risk of dosing errors. Using pharmacies to compound antibiotics raises the theoretical risk of introducing contaminants or adjuvants that can cause toxic anterior segment syndrome.

Others have raised concerns that routine intraocular antibiotic prophylaxis can lead to increasing bacterial drug resistance. The recent editorial by Naseri et al77 effectively quiets this concern because a 1-time, highly concentrated dose of antibiotic injected into a physiologically isolated space is extremely unlikely to promote bacterial resistance. In fact, the concern over promoting antibiotic resistance should be directed more toward the common use of topical antibiotic prophylaxis.78 Posterior capsular rupture is one of the greatest risk factors for infectious endophthalmitis. There is strong evidence that intracameral antibiotics reduce the risk of endophthalmitis in eyes with this complication, and this is true of both cefuroxime72 and moxifloxacin.33

In summary, there is much stronger evidence supporting the efficacy of intracameral antibiotic injection than for topical administration for endophthalmitis prophylaxis. Despite weaker evidence for efficacy, topical antibiotic prophylaxis is ubiquitous and the most common method in use. This is because it is considered safe and readily available. In countries where an approved antibiotic formulation for intraocular use is commercially available, adoption is increasingly widespread. Where no such commercial source is available, the rare incidence of bacterial endophthalmitis must be weighed against the theoretical risks of using compounded formulations or those mixed by the operating room staff. In addition to theoretical compounding risks, vancomycin poses the additional risk of HORV. Although rare, it can result in bilateral blindness when used for close sequential surgery. If a commercial formulation is not available, surgeons must individually weigh the potential benefits and risks of using or not using an intracameral injection.

REFERENCE

1. Sandvig KU, Dannevig L. Postoperative endophthalmitis: establishment and results of a national registry. J Cataract Refract Surg. 2003;29:1273-1280.
2. Taban M, Beherens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of literature. Arch Ophthalmol. 2005; 123:613-620.
3. Kessel L, Flesner P, Andresen J, et al. Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis. Acta Ophthalmol. 2015;93:303-317.
4. West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology. 2005;112:1388-1394.
5. Lundstrom M, Wejde G, Stenevi U, et al. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology. 2007;114:866-870.
6. Colleaux KM, Hamilton WK. Effect of prophylactic antibiotics and incision type on the incidence of endophthalmitis after cataract surgery. Can J Ophthalmol. 2000;35:373-378.
7. Fintelmann R, Naseri A. Prophylaxis of postoperative endophthalmitis following cataract surgery. Drugs. 2010;70:1395-1409.
8. Norregaard JC, Thoning H, Bernth-Petersen P, et al. Risk of endophthalmitis after cataract extraction: results from the International Cataract Surgery Outcomes study. Br J Ophthalmol. 1997;81:102-106.
9. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978-988.
10. Keay L, Gower EW, Cassard SD, et al. Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology. 2012;119:914-922.
11. Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. http://www.escrs.org/downloads/endophthalmitis-guidelines.pdf. 2013.
12. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravitreous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479-1496.
13. Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;115:473-476.
14. Gower EW, Keay LJ, Stare DE, et al. Characteristics of endophthalmitis after cataract surgery in the United States Medicare population. Ophthalmology. 2015;122:1625-1632.
15. Behndig A, Cochener B, Güell JL, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39:1421-1431.
16. Nguyen CL, Oh LJ, Wong E, et al. Povidone-iodine 3-minute exposure time is viable in preparation for cataract surgery. Eur J Ophthalmol. April 7, 2017. [Epub ahead of print].
17. Sadaka A, Durand ML, Gilmore MS. Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection. Prog Retin Eye Res. 2012;31:316-331.
18. Levison AL, Mendes TS, Bhisitkul R. Post procedural endophthalmitis: a review. Expert Rev Ophthalmol. 2013;8:45-62.
19. Charles QY, Ta CN. Prevention of postcataract endophthalmitis: evidence-based medicine. Curr Opin Ophthalmol. 2012;23:19-24.
20. Galor A, Goldhardt R, Wellik SR, et al. Management strategies to reduce risk of postoperative infections. Curr Ophthalmol Rep. 2013;1:161-168.
21. Tan CS, Wong HK, Yang FP. Epidemiology of postoperative endophthalmitis in an Asian population: 11-year incidence and effect of intracameral antibiotic agents. J Cataract Refract Surg. 2012;38:425-430.
22. Keynan Y, Finkelman Y, Lagacé-Wiens P. The microbiology of endophthalmitis: global trends and a local perspective. Eur J Clin Microbiol Infect Dis. 2012;31:2879-2886.
23. Nentwich MM, Ta CN, Kreutzer TC, et al. Incidence of postoperative endophthalmitis from 1990 to 2009 using povidone-iodine but no intracameral antibiotics at a single academic institution. J Cataract Refract Surg. 2015;41:58-66.
24. Shimada H, Arai S, Nakashizuka H, et al. Reduced anterior chamber contamination by frequent surface irrigation with diluted iodine solutions during cataract surgery. Acta Ophthalmol. March 8, 2017. [Epub ahead of print].
25. Hierholzer S, Hierholzer G. Polyvinylpyrrolidone iodine in accident surgery. Unfallchirurgie. 1985;11:309-315.
26. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology. 2002;109:13-24.
27. Braga-Mele R, Chang DF, Henderson BA, et al. Intracameral antibiotics: safety, efficacy, and preparation. J Cataract Refract Surg. 2014;40:2134-2142.
28. Nanavaty MA, Wearne MJ. Perioperative antibiotic prophylaxis during phaco-emulsification and intraocular lens implantation: national survey of smaller eye units in England. Clin Exp Ophthalmol. 2010;38:462-466.
29. Yu-Wai-Man P, Morgan SJ, Hildreth AJ, et al. Efficacy of intracameral and subconjunctival cefuroxime in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34:447-451.
30. Liesegang TJ. Perioperative antibiotic prophylaxis in cataract surgery [erratum in Cornea. 2000;19:123]. Cornea. 1999;18:383-402.
31. Gordon-Bennett P, Karas A, Flanagan D, et al. A survey of measures used for the prevention of postoperative endophthalmitis after cataract surgery in the United Kingdom. Eye (Lond). 2008;22:620-627.
    32. García-Sáenz MC, Arias-Puente A, Rodríguez-Caravaca G, et al. Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery; ten-year comparative study. J Cataract Refract Surg. 2010;36:203-207.
    33. Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600,000 surgeries. Ophthalmology. 2017;124:768-775.
    34. Gentile RC, Shukla S, Shah M, et al. Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology. 2014;121:1634-1642.
    35. Haripriya A, Lalitha P, Mathen M, et al. Nocardia endophthalmitis after cataract surgery: clinicomicrobiological study. Am J Ophthalmol. 2005; 139:837-846.
    36. Moloney TP, Park J. Microbiological isolates and antibiotic sensitivities in culture-proven endophthalmitis: a 15-year review. Br J Ophthalmol. 2014; 98:1492-1497.
    37. Grzybowski A, Kuklo P, Pieczynski J, et al. A review of preoperative manoeuvres for prophylaxis of endophthalmitis in intraocular surgery: topical application of antibiotics, disinfectants, or both? Curr Opin Ophthalmol. 2016;27:9-23.
    38. Olson RJ, Braga-Mele R, Chen SH, et al; American Academy of Ophthalmology Preferred Practice Pattern Cataract and Anterior Segment Panel. Cataract in the adult eye preferred practice pattern. Ophthalmology. October 13, 2016. [Epub ahead of print].
    39. Balestrazzi A, Malandrini A, Montagnani F, et al. Phacoemulsificator and sterile drapes contamination during cataract surgery: a microbiological study. Eur J Ophthalmol. 2012;22:188-194.
    40. Kumar MA, Kurien SS, Selvaraj S, et al. Comparison of different techniques of cataract surgery in bacterial contamination of the anterior chamber in diabetic and non-diabetic population. Indian J Ophthalmol. 2012;60:41-44.
    41. Chang DF, Braga-Mele R, Henderson BA, et al. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2014 ASCRS member survey. J Cataract Refract Surg. 2015;41:1300-1305.
    42. Chang DF, Braga-Mele R, Mamalis N, et al. Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey. J Cataract Refract Surg. 2007;33:1801-1805.
    43. Montan PG, Wejde G, Koranyi G, et al. Prophylactic intracameral cefuroxime; efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg. 2002;28:977-981.
    44. Montan PG, Wejde G, Setterquist H, et al. Prophylactic intracameral cefuroxime; evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg. 2002;28:982-987.
    45. Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J Cataract Refract Surg. 2006;32:407-410.
    46. Wejde G, Montan P, Lundstrom M, et al. Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999-2001. Acta Ophthalmol Scand. 2005;83:7-10.
    47. Barry P. Adoption of intracameral antibiotic prophylaxis of endophthalmitis following cataract surgery; update on the ESCRS Endophthalmitis Study. J Cataract Refract Surg. 2014;40:138-142.
    48. García-Sáenz MC, Arias-Puente A, Rodríguez-Caravaca G, et al. Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery; ten-year comparative study. J Cataract Refract Surg. 2010;36:203-207.
    49. van der Merwe J, Mustak H, Cook C. Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa. J Cataract Refract Surg. 2012; 38:2054.
    50. Barreau G, Mounier M, Marin B, et al. Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study. J Cataract Refract Surg. 2012;38:1370-1375.
    51. Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013;39:8-14.
    52. Arshinoff SA, Bastianelli PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg. 2011;37:2105-2114.
    53. Jabbarvand M, Hashemian H, Khodaparast M, et al. Endophthalmitis occurring after cataract surgery; outcomes of more than 480,000 cataract surgeries, epidemiologic features, and risk factors. Ophthalmology. 2016; 123:295-301.
    54. Creuzot-Garcher C, Benzenine E, Mariet AS, et al. Incidence of acute postoperative endophthalmitis after cataract surgery: a nationwide study in France from 2005 to 2014. Ophthalmology. 2016;123:1414-1422.
    55. Garat M, Moser CL, Alonso-Tarres C, et al. Intracameral cefazolin to prevent endophthalmitis in cataract surgery: 3-year retrospective study. J Cataract Refract Surg. 2005;31:2230-2234.
    56. Romero P, Mendez I, Salvat M, et al. Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery. J Cataract Refract Surg. 2006; 32:438-441.
    57. Behndig A. What the Swedish National Cataract Database can tell us. Paper presented at: 20th Congress of the European Ophthalmological Society; June 7, 2015; Vienna, Austria.
    58. Villada JR, Vicente U, Javaloy J, et al. Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery. J Cataract Refract Surg. 2005;31:620-621.
    59. Moisseiev E, Levinger E. Anaphylactic reaction following intracameral cefuroxime injection during cataract surgery. J Cataract Refract Surg. 2013; 39:1432-1434.
    60. Witkin AJ, Shah AR, Engstrom RE, et al. Postoperative hemorrhagic occlusive retinal vasculitis; expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015;122:1438-1451.
    61. Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis, clinical characteristics of 36 eyes. Ophthalmology. 2017;124:583-595.
    62. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue [letter]. Arch Ophthalmol. 2005;123:1282-1283.
    63. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49:S79-S83.
    64. Kim DH, Stark WJ, O'Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992-1996.
    65. Holland EJ, McDonald MB, Parekh JG, et al. Antibiotic resistance in acute postoperative endophthalmitis. Ophthalmology. 2014;121:S1-S12.
    66. Arshinoff SA, Modabber M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J Cataract Refract Surg. 2016;42:1730-1741.
    67. Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34: 1114-1120.
    68. Haripriya A, Chang DF, Namburar S, et al. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at Aravind Eye Hospital. Ophthalmology. 2016;123:302-308.
    69. Gower EW, Lindsley K, Tulenko SE, et al. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:CD006364.
    70. Rodriguez-Caravaca G, García-Sáenz MC, Villar-Del-Campo MC, et al. Incidence of endophthalmitis and impact of prophylaxis with cefuroxime on cataract surgery. J Cataract Refract Surg. 2013;39:1399-1403.
    71. Friling E, Lundström M, Stenevi U, et al. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39:15-21.
    72. Matsuura K, Miyoshi T, Suto C, et al. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg. 2013;39:1702-1706.
    73. Herrinton LJ, Shorstein NH, Paschal JF, et al. Comparative effectiveness of antibiotic prophylaxis in cataract surgery. Ophthalmology. 2016;123:287-294.
    74. Daien V, Papinaud L, Gillies MC, et al. Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of endophthalmitis after cataract surgery with or without perioperative capsular rupture. JAMA Ophthalmol. 2016;134:810-816.
    75. Javitt JC. Intracameral antibiotics reduce the risk of endophthalmitis after cataract surgery: does the preponderance of the evidence mandate a global change in practice? Ophthalmology. 2016;123:226-231.
    76. Grzybowski A, Schwartz SG, Matsuura K, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns around the world. Curr Pharm Des. 2017;23:565-573.
    77. Naseri A, Melles RB, Shorstein NH. Intracameral antibiotics in the shadow of hemorrhagic occlusive retinal vasculitis. Ophthalmology. 2017;124:580-582.
    78. Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology. 2011;118:1358-1363.
    Keywords:

    endophthalmitis prophylaxis; povidone-iodine; perioperative antibiotics; intracameral antibiotic prophylaxis

    © 2017 by Asia Pacific Academy of Ophthalmology